Spinal Restoration, Inc. Receives Patent Allowance for the Biostat® System

Spinal Restoration, Inc. Receives Patent Allowance for the Biostat® System

Share this story with your network

AUSTIN, Texas–(BUSINESS WIRE)–Spinal Restoration, Inc. announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for claims concerning the delivery device and method of use of the Biostat System for the treatment of discogenic low back pain.

“We believe that the design of the Biostat System overcomes significant hurdles to safe delivery of biologic materials to the intervertebral disc. The allowance of these claims strengthens Spinal Restoration’s broad intellectual property portfolio and helps to fortify our leadership position in the field of intradiscal biologic therapies.”

The Biostat System consists of BIOSTAT BIOLOGX® Fibrin Sealant, a human derived, biologic tissue sealant, and the Biostat® Delivery Device, a unique application system specifically designed for safe delivery of biologic materials to the intervertebral disc. The allowed claims are directed to the Biostat Delivery Device as well as kits and methods for using the Biostat System to treat the intervertebral disc.

President and CEO Gary Sabins commented, “We believe that the design of the Biostat System overcomes significant hurdles to safe delivery of biologic materials to the intervertebral disc. The allowance of these claims strengthens Spinal Restoration’s broad intellectual property portfolio and helps to fortify our leadership position in the field of intradiscal biologic therapies.”

In March of 2010, Spinal Restoration became the first company to initiate a Phase III study of a biologic therapy for discogenic low back pain. The 260 patient Phase III study is currently enrolling subjects at 20 centers across the U.S. If successful, the Biostat System Phase III study could have an extensive, far-reaching impact on the diagnosis and treatment of discogenic chronic low back pain—a debilitating health condition that affects an estimated four million adults in the U.S. annually.

More detailed information about the Biostat System study is available at www.clinicaltrials.gov (Study Identifier: NCT01011816) and at www.lowbackstudy.com.

About Spinal Restoration

Spinal Restoration restores patients’ lives by delivering new therapies that address unmet needs in spine health management. These therapies are minimally invasive, early interventions with clinically proven results. The company is working with a diverse, highly regarded group of clinical and scientific advisors to develop the Biostat System, a proprietary resorbable biologic and delivery system for the treatment of chronic disc pain. Visit www.spinalrestoration.com for more information.

Leave a Comment

Your email address will not be published. Required fields are marked *

*